key: cord-0864059-k0ajui0p
authors: Jenks, Jeffrey D; Aslam, Saima; Horton, Lucy E; Law, Nancy; Bharti, Ajay; Logan, Cathy; Taremi, Mahnaz; Vaida, Florin; Ritter, Michele
title: Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients with COVID-19
date: 2021-06-06
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab522
sha: f9173b515ee875c80b204fddd8ee4654c225dd35
doc_id: 864059
cord_uid: k0ajui0p

nan

M a n u s c r i p t 2 Dear Editor:

We read with interest the article by Kumar and colleagues, who reported good experience with the neutralizing monoclonal antibody (mAb) bamlanivimab [1] . We developed a COVID-19 clinic during pandemic surge conditions and prioritized mAb infusion to high-risk patients, particularly with casirivimab/imdevimab, and would like to share our experience given limited data published on the efficacy of casirivimab/imdevimab.

We performed a retrospective review of medical records of patients referred to our clinic from 11/1/2020-2/28/2021 and included only those >18 years and considered high-risk.

Patients were defined as high-risk (and assigned a risk score) if they met >1 criteria: age >65 years (3 points), body mass index >35 (3 points), age >55 years with hypertension, coronary artery disease or chronic lung disease (2 points), diabetes mellitus, chronic kidney disease, or immunosuppression (2 points each). One additional point was assigned for Black, Native American, and/or Hispanic/Latino ethnicity. Casirivimab/imdevimab or bamlanivimab was offered to all high-risk outpatients within 5 days of COVID-19 diagnosis via positive polymerase chain reaction. We extracted baseline demographics, medical comorbidities, receipt of mAb, and 30-day outcomes including hospitalization and death related to COVID-19.

We performed unadjusted analyses used Fisher's exact test and t-test; and multivariate analysis using logistic regression controlling for risk score and local pandemic intensity.

Sensitivity analyses did not find other significant predictors. Tests were 2-sided with an α level of .05 and performed using Stata version 12.1 (StataCorp) and R. The study was Among 617 patients, 175 received mAb and 442 did not (control). The mAb group was older, had more men, more comorbidities, and a higher risk score. Casirivimab/imdevimab was given in 83.4% and bamlanivimab 16.6%. The majority (94%) received mAb within 5 days of symptom onset. There was a significant reduction in hospitalizations in the mAb group vs.

control (1.7% vs. 24%, p<0.005) ( Table) , which was noted in the subset of patients only seen in our Telemedicine Clinic as well. Notably, there were no COVID-19-related deaths in the mAb group vs. 12 (2.7%) in controls (p=0.024). Mean length of stay for COVID-19related hospitalization was shorter in those that received mAb, though not statistically significant. The number needed to treat (NNT) to prevent one hospitalization was 4.5.

Hospitalization and mortality within 30 days were independently associated with receipt of mAb and the risk score via multivariate analysis.

Similar to the experience of Kumar and colleagues with bamlanivimab, we found that mAb receipt, primarily with casirivimab/imdevimab, was associated with a significant reduction in hospitalization. Unlike Kumar and colleagues, though, we found a lower mortality rate in the mAb group compared to controls and our NNT of 4.5 to prevent one hospitalization was lower than what they report. The significant reduction in COVID-19 related hospitalizations and death with early mAb administration should prompt more widespread use and 

Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study

We acknowledge the tremendous efforts of the COVID-19 Clinic Team: Dr. Ajay Bharti, Dr. Constance Benson as leaders of the COVID-19 Therapeutics Committee at UCSD and input into development of the risk score.

M a n u s c r i p t